Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07132983 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 4
- Study locations
NCT07132983 is a Phase 2 study of Chronic Obstructive Pulmonary Disease that has completed, run by Verona Pharma. The registered enrollment target is 33 participants, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT07132983, a Phase 2 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Verona Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will assess the pharmacokinetics (PK), pharmacodynamics (PD) and safety of ensifentrine and glycopyrrolate fixed dose (FDC) product, the individual components of the FDC (ensifentrine and glycopyrrolate, each in the FDC formulation), ensifentrine 1.5 mg in the FDC formulation and ensifentrine 3 mg in the marketed formulation each administered via a standard jet nebulizer, in adult participants with chronic obstructive pulmonary disease (COPD).
Conditions Studied
Interventions
- DRUG Ensifentrine 3 mg
- DRUG Glycopyrrolate 42.5 mcg
- DRUG Ensifentrine 1.5 mg
- DRUG Ensifentrine 3 mg (marketed formulation)
Study Locations (4)
Florida
- Clinical Research of West Florida Inc - Clearwater - Clearwater
- Clinical Research of West Florida Inc - Tampa - Tampa
Missouri
- Midwest Chest Consultants PC - Saint Charles
South Carolina
- Velocity Clinical Research - Spartanburg - PPDS - Spartanburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-10-06 |
| Est. Completion | 2025-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07132983
The ClinicalTrials.gov registry entry for NCT07132983 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower). The listed sponsor is Verona Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 4 interventions - of which Ensifentrine 3 mg is the first listed.
NCT07132983 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, Missouri, South Carolina.
Frequently Asked Questions
What is clinical trial NCT07132983 about?
NCT07132983 is a clinical study titled "A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease". This study will assess the pharmacokinetics (PK), pharmacodynamics (PD) and safety of ensifentrine and glycopyrrolate fixed dose (FDC) product, the individual components of the FDC (ensifentrine and glycopyrrolate, each in the FDC formulation), ensifentrine 1.5 mg in the FDC formulation and ensifent...
What is the current status of trial NCT07132983?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2025-10-06. Estimated completion is 2025-11-28.
What conditions does trial NCT07132983 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT07132983?
The interventions under investigation include: Ensifentrine 3 mg (DRUG), Glycopyrrolate 42.5 mcg (DRUG), Ensifentrine 1.5 mg (DRUG), Ensifentrine 3 mg (marketed formulation) (DRUG).
Who is sponsoring clinical trial NCT07132983?
This trial is sponsored by Verona Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07132983 being conducted?
This trial has 4 study locations across Florida, Missouri, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.